Is elevated TMAO with above-optimal hs-CRP a plausible gut-cardiovascular pattern?

At age 71, concurrent elevation of TMAO and hs-CRP may provide biologically coherent context for cardiovascular risk, but it is not a validated diagnostic entity or a basis for biomarker-directed treatment.

Microbial and inflammatory biology

• Active gut microbial pathways can generate trimethylamine (TMA) from choline and carnitine-related substrates. Emergencia timonensis uses the bbu pathway to convert γ-butyrobetaine to TMA and was enriched in high TMAO responders after carnitine challenge; choline conversion through CutC/CutD is another established route.
• Following hepatic conversion of TMA to TMAO, experimental endothelial models show activation of p38/ERK MAPK and NF-κB, with increased COX-2, IL-6, E-selectin, ICAM-1, leukocyte adhesion, and inflammatory pathways involving ROS–TXNIP–NLRP3 and HMGB1–TLR4. These mechanisms make an inflammation-linked vascular effect biologically plausible.

Clinical and prognostic evidence

• hs-CRP ≥2 mg/L is an ACC/AHA cardiovascular risk-enhancing factor in selected primary-prevention decisions.
• Higher TMAO has observational associations with cardiovascular events and mortality, although findings vary across populations.
• In a prospective cohort of patients with acute myocardial infarction complicated by heart failure, higher TMAO predicted major adverse cardiovascular events only when hs-CRP was above the median (6.68 mg/L), with a significant TMAO-by-hs-CRP interaction. This supports prognostic plausibility in that high-risk setting, not causation or generalization to stable primary prevention.

Interpretation

• TMAO reflects not only intestinal TMA generation but also diet, hepatic metabolism, comorbidity, and especially renal clearance. In chronic kidney disease, TMAO correlations with hs-CRP, IL-6, and fibrinogen disappeared after GFR adjustment.
• Static microbiome gene abundance does not reliably indicate actual TMA production, which depends on substrate exposure and microbial activity.

Bottom line

• Elevated TMAO plus above-optimal hs-CRP is a plausible, investigational gut–inflammation–cardiovascular pattern. It should prompt conventional cardiovascular risk assessment and attention to reversible contributors, rather than routine TMAO testing or a stand-alone clinical diagnosis.